At a glance
ClinicalIndex Comparison Record- ✓Men and postmenopausal women
- ✓Age 45 years or older
- ✓Diagnosed with Mild Cognitive Impairment or cognitively healthy
- ✕Neurological disease including stroke, seizure, Parkinson's, Alzheimer's, traumatic brain injury with loss of consciousness >30 minutes, multiple sclerosis, or brain infection/meningitis
- ✕Baseline IQ below 85
- ✕Major psychiatric illness (schizophrenia, bipolar disorder) or substance abuse
- ✕Severe cardiovascular disease (including pacemaker), COPD, liver or kidney disease, or inflammatory illness
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cognitive Enhancement Through Transcranial Laser Therapy
In Brief
A Phase 2 clinical trial evaluating LLLT and Placebo for Healthy Participants and Mild Cognitive Impairment. Completed, enrolled 91 participants across 1 site.
Detailed Summary
This is a mechanism-driven translational project to test the efficacy of transcranial low-level light/laser therapy (LLLT), for enhancing cognitive function in middle-aged and older adults and participants with Mild Cognitive Impairment.
Study Details
Timeline
Interventions
The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.